ARCHIVES

BMS, Exelixis To Collaborate On Drug Development.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

Phase III Lung and Pancreatic Cancer Trials Are Stopped

April 30, 2010

NCI Advisors To Gain Increased Responsibility For Concept, Technical Merit Review Of Contracts

December 19, 1980

In Brief: Subcommittee Okays $980 Million for NCI In 1983, House Passes Waxman Bill, With Centers Line Item

October 8, 1982

NCI Advisory Group, Other Cancer Meetings

February 24, 1984

Guest Commentary: Donald Berry Finds Fundamental Flaws In Data Pooling Plan.

November 16, 2007